RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Pipeline Review, H1 2016

  • ID: 3802771
  • Report
  • 60 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Basilea Pharmaceutica AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Redx Pharma Plc
  • Sirnaomics, Inc.
  • MORE
RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Pipeline Review, H1 2016

Summary

‘RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Pipeline Review, H1 2016’, provides in depth analysis on RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1)
- The report reviews RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Basilea Pharmaceutica AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Redx Pharma Plc
  • Sirnaomics, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) Overview

Therapeutics Development

RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Products under Development by Stage of Development

RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Products under Development by Therapy Area

RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Products under Development by Indication

RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Products under Development by Companies

RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Basilea Pharmaceutica AG

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Hanmi Pharmaceuticals, Co. Ltd.

Millennium Pharmaceuticals, Inc.

Novartis AG

Redx Pharma Plc

Sirnaomics, Inc.

VG Life Sciences, Inc.

RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Drug Profiles

BAL-3833 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-95573 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydroxychloroquine + sorafenib tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LXH-254 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3009120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7304 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Pan-RAF Kinase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Pan-Raf Kinases for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-503 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-580 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEW-0201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Dormant Projects

RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Discontinued Products

RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) - Featured News & Press Releases

Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting

Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting

Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent

Apr 22, 2015: Deciphera Pharmaceuticals Presents Data Highlighting pan-RAF inhibitor Cetuximab including Proprietary and Partnered Programs at AACR 2015 Annual Meeting

Apr 20, 2015: Lilly Releases Early-Stage Pipeline Data On LY3009120 at AACR Annual Meeting 2015

Nov 10, 2014: Hanmi To Initiate A Phase 1 Clinical Trial Of HM95573, The Next Generation Targeted Therapy For Melanoma Treatment

Sep 04, 2014: VG Life Sciences Progress Update Phase I Cancer Study

Apr 07, 2014: Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for LY3009120

Mar 14, 2014: VG Life Sciences's Reports on Clinical Outcomes in Phase I Cancer Study

Dec 13, 2013: VG Life Sciences Update on Phase I Cancer Study

Jul 25, 2013: VG Life Sciences Reports on Scientific Advancements: Completion of Third Cohort of Phase I Clinical Trial; Grant from the American Heart Association;

Apr 04, 2013: VG Life Sciences Reports Positive Safety Results Of Hydroxychloroquine And Sorafenib Combination Therapy In Second Cohort Of Phase I Solid Tumor Study

Jan 31, 2013: VG Life Sciences Reports Positive Results From Phase I Ovarian Cancer Trial Using Sorafenib Combined With Hydroxychloroquine

Jan 14, 2013: VG Life Sciences Receives IRB Approval To Expand Phase I Cancer Trial Of Hydroxychloroquine In Combination With Sorafenib

Jul 19, 2012: Viral Genetics Begins Phase I Clinical Trial For Ovarian Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 60List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Basilea Pharmaceutica AG, H1 2016

Pipeline by Eli Lilly and Company, H1 2016

Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016

Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by Redx Pharma Plc, H1 2016

Pipeline by Sirnaomics, Inc., H1 2016

Pipeline by VG Life Sciences, Inc., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Discontinued Products, H1 2016 47List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Basilea Pharmaceutica AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Redx Pharma Plc
  • Sirnaomics, Inc.
  • MORE
According to the author's, recently published report 'RAF Proto-Oncogene SerineThreonine-Protein Kinase - Pipeline Review, H1 2016'; RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies.

Furthermore, the author says; RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.

The report 'RAF Proto-Oncogene SerineThreonine-Protein Kinase - Pipeline Review, H1 2016' outlays comprehensive information on the RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in RAF Proto-Oncogene Serine/Threonine-Protein Kinase (C-Raf Kinase or Proto-Oncogene c-RAF or Raf-1 or EC 2.7.11.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 3 and 1 respectively.
Note: Product cover images may vary from those shown
5 of 5
Basilea Pharmaceutica AG
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Millennium Pharmaceuticals, Inc.
Novartis AG
Redx Pharma Plc
Sirnaomics, Inc.
VG Life Sciences, Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll